Home › Endometrial Cancer › Michigan
Endometrial Cancer clinical trials in Michigan
43 studies for Endometrial Cancer are looking for participants at sites in Michigan.
Cities in Michigan
- Detroit21 studies
- Grand Rapids18 studies
- Ann Arbor9 studies
- Farmington Hills4 studies
- Wyoming3 studies
- Kalamazoo3 studies
- Lansing3 studies
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- and 37 more
RecruitingPhase 2
All ages · All sexes · Updated Oct 2, 2026 · NCT05564377A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- South Texas Accelerated Research Therapeutics (START), Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
- Bronson Battle Creek, Battle Creek
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- and 25 more
RecruitingPhase 3
Ages 18 and older · Women · Updated Oct 2, 2026 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06760819177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- BAMF Health, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT07189871Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Henry Ford Health, Detroit
- Valley OB-GYN Clinic, Saginaw
RecruitingObservational study
Ages 18 and older · Women · Updated Sep 29, 2026 · NCT05051722Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- Bronson Battle Creek, Battle Creek
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
- and 7 more
RecruitingPhase 2
Ages 18 and older · Women · Updated Sep 28, 2026 · NCT05112601A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · Women · Updated Sep 24, 2026 · NCT04590326Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Grand Rapids
RecruitingPhase 2
Ages 18 to 130 · All sexes · Updated Sep 23, 2026 · NCT05489211Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07213609ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- Corewell Health, Grand Rapids
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 9, 2026 · NCT07166094A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- South Texas Accelerated Research Therapeutics (START) Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06400472DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Ann Arbor
RecruitingPhase 3
Ages 18 and older · Women · Updated Sep 3, 2026 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 15 and older · All sexes · Updated Aug 25, 2026 · NCT06276491Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- C S Mott Children's Hospital, Ann Arbor
RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Detroit
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 21, 2026 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Karmanos Cancer Institute, Detroit
RecruitingPhase 2
Ages 18 and older · Women · Updated Aug 21, 2026 · NCT05548296A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Karmanos Cancer Center, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07470853A Study of PHST001 in Advanced Solid Tumors
- University of Michigan Rogel Cancer Center, Ann Arbor
- START Center for Cancer Research - Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06840886A Study of MGC026 in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT05592626Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- START - Midwest, Grand Rapids
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07444814Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Karmanos Cancer Institute, Detroit
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT05579366Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Ann Arbor
- Research Site, Ann Arbor
RecruitingPhase 3
Ages 18 and older · Women · Updated Jul 29, 2026 · NCT07044336Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
- Investigative Site #120, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT06974110A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
- Karmanos Cancer Institute, Farmington Hills
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT05208762First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Henry Ford Health Hospital, Detroit
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Karmanos Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 18, 2026 · NCT07503808A Study of Lorigerlimab in Participants With Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 2
Ages 18 and older · Women · Updated Jun 2, 2026 · NCT06730347Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Henry Ford Cancer Institute, Detroit
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 17, 2025 · NCT05856981A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- START Midwest, Grand Rapids
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Dec 11, 2025 · NCT06943521A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- University of Michigan, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
- Barbara Ann Karmanos Cancer Hospital, Detroit
RecruitingPhase 2
Ages 18 to 70 · Women · Updated Oct 30, 2025 · NCT06481592SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Ann Arbor
- Massive Bio SYNERGY-AI site, Lansing
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
- University of Michigan, Ann Arbor
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2025 · NCT05941507From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.